June 1 2020 | Targeted Therapies in Oncology

July 04, 2020

According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.

July 03, 2020

"Since 2008, 1748 community oncology clinics and/or practices have closed, been acquired by hospitals, undergone corporate mergers, or reported financial difficulties."

June 29, 2020

Broad adoption of testing methods that allow for assessing all possible actionable targets and diagnostic markers in advanced cancer is becoming more complex with greater availability of lifesaving targeted therapies.

June 29, 2020

A review of selected trials looking at frequencies of grade 3 irAEs suggests that renal and bone marrow toxicities occur more frequently with the use of PD-1 and PD-L1 inhibitors compared with agents blocking CTLA-4

June 28, 2020

With multiple treatment options available in the ovarian cancer landscape, experts are now looking for an answer to the challenging question of optimal sequencing.

June 27, 2020

In patients with advanced melanoma whose disease progressed on immunotherapy, the use of fecal microbiota transplant achieved objective responses, in a phase I study.

June 27, 2020

Experts say the combining intralesional therapies with immunotherapy is a strategy that has potential to expand into medical practices outside of the oncology realm.

June 25, 2020

In an interview with Targeted Therapies in Oncology, C. Ola Landgren, MD, PhD, discussed how the availability of daratumumab by subcutaneous administration will affect clinical practice going forward.

June 22, 2020

Treatment of glioblastoma has seen few advancements since the approval of temozolomide plus radiotherapy in 2005 for newly diagnosed disease. Recently, promising clinical data have reinvigorated hope for novel therapies in this tumor type.

June 21, 2020

Oncology practices like Northwest Medical Specialties are looking for ways to improve their patient care and are willing to transform their practice to do so.

June 20, 2020

“We are starting to see more and more patients with recurrent ovarian cancer, we’re treating them much more aggressively in the up-front setting, and we have to face PARP inhibitor resistance in the future.”

June 20, 2020

“We’ve seen remote data monitoring and remote data capturing. We are in a situation to continue moving forward, even in the midst of the pandemic, and, in fact, accelerate our position."

June 19, 2020

"In all, these 3 exciting trials combining PD-1 or PD-L1 inhibition with targeted therapy, chemotherapy, or immune cell therapy bode well for evolving advances with this tolerable class of agents."

June 19, 2020

Management of treatment-associated dermatologic adverse events that commonly occur as a result of cytotoxic or targeted therapy is critical to prevent dose modifications or interruptions that could negatively affect clinical outcomes.